This is a working overview of peptide analog, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-05-03. Anything still debated is marked as such rather than presented as settled.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide fragment | Not a full hormone |
| Molecular target | Proposed adipose tissue lipolysis | Receptor details uncertain |
| Typical research dose | Not established for clinical use | Doses vary across studies |
| Stability in solution | Limited; store cold | Avoid repeated freeze-thaw |
| Regulatory status | Not approved as a drug | Varies by country |
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
Lula attended the 15th BRICS summit in August 2023. During the event he spoke in favour of more countries joining the BRICS, including Brazil's neighbour Argentina and Indonesia; called for a common currency between BRICS members and said the group is not meant to challenge either the G7 or the US. Lula criticized the United Nations Security Council which he considered to be "limited" in face of the 2022 Russian invasion of Ukraine and reiterated Brazil's position of "defending sovereignty, territorial integrity" and the principles of the United Nations.
=== Preclinical === AM-510 – undefined mechanism of action – opioid-related disorders ATI-1013 – monoclonal antibody against nicotine – smoking withdrawal CTRX-1001 – immunostimulant – opioid-related disorders CTRX-2001 – immunostimulant – opioid-related disorders Cyclobenzaprine (KRL-102; TNX-102; Tonmya; VLD-cyclobenzaprine) – tricyclic antidepressant (various actions) – alcoholism Cyproheptadine/prazosin (KT-110; Periactine/Alpress) – combination of cyproheptadine (various actions) and prazosin (α1-adrenergic receptor antagonist) – cocaine-related disorders Dimethyltryptamine (DMT; EBRX-101) – non-selective serotonin receptor agonist, serotonin 5-HT2A receptor agonist, and serotonergic psychedelic – alcoholism EQL-101 – undefined mechanism of action (non-hallucinogenic non-cardiotoxic ibogaine derivative) – substance use disorders Flumazenil/naloxone transdermal patch (MX-1607; RescuePatch) – combination of flumazenil (GABAA receptor negative allosteric modulator/benzodiazepine antagonist) and naloxone (opioid receptor antagonist) – substance-related disorders GM-3009 – κ-opioid receptor agonist (noribogaine analogue) – opioid-related disorders INDV-1000 (GABAB PAM) – GABAB receptor positive allosteric modulator – substance-related disorders KB-128 – serotonin 5-HT2C receptor G protein-biased agonist, serotonin 5-HT2A and 5-HT2B receptor antagonist – alcoholism LPH-48 – undefined mechanism of action and serotonergic psychedelic ((shorter-acting LPH-5 analogue) – alcoholism M-101 – GABA receptor antagonist – substance-related disorders 5-Methoxy-2-aminoindane (MEAI; 5-MeO-AI; CMND-100) – serotonin–norepinephrine releasing agent – cocaine-related disorders Metyrapone/oxazepam (EMB-001C; EMB-001) – combination of metyrapone (11β-hydroxylase inhibitor and cortisol synthesis inhibitor) and oxazepam (benzodiazepine/GABAA receptor positive allosteric modulator) – substance-related disorders Midomafetamine microneedle transdermal patch (MDMA; ecstasy) – serotonin, norepinephrine, and dopamine releasing agent, weak serotonin 5-HT2 receptor agonist, entactogen – substance-related disorders Naltrexone controlled-release (BICX101, BICX-101) – opioid receptor antagonist – alcoholism, opioid-related disorders Nicotine degrading enzyme (ATI-3009; NicA2; NicA2-J1) – enzyme – smoking withdrawal PPL-138 (BU10038, BU-10038) – nociceptin receptor agonist, μ-opioid receptor agonist, opioid peptide agonist – alcoholism, cocaine-related disorders PSIL-001 (DMT analogue) – non-hallucinogenic serotonin 5-HT1 receptor modulator – substance-related disorders PSIL-002 (DMT analogue) – non-hallucinogenic serotonin 5-HT1 receptor modulator – substance-related disorders Psilacetin (O-acetylpsilocin; 4-AcO-DMT) – non-selective serotonin receptor agonist, serotonin 5-HT2A receptor agonist, serotonergic psychedelic – substance-related disorders Pudafensine (IP-2015; IP-2017; IPNP-2015; IPTN-2021) – serotonin–norepinephrine–dopamine reuptake inhibitor – substance-related disorders Research programme: psychedelic-based neurological therapeutics - Psilera – undefined mechanism of action and serotonergic psychedelics – alcoholism Research programme: psychoplastogen therapeutics - Collaborations Pharmaceuticals – undefined mechanism of action – opioid-related disorders SVN-015 – serotonin–dopamine reuptake inhibitor – substance-related disorders SXC-2023 – cystine–glutamate antiporter (SLC7A11; System xc- or Sxc) activator – cocaine-related disorders, smoking withdrawal [15] [16] TACT411 – serotonin 5-HT1B receptor modulator and monoamine transporter modulator – alcoholism TACT523 – undefined mechanism of action – alcoholism TACT833 – serotonin 5-HT1B receptor modulator and monoamine transporter modulator – alcoholism VS-01 (VS-01-HAC) – ammonia scavenger – substance-related disorders
== References == Charpin, Dominique (2010). Writing, Law, and Kingship in Old Babylonian Mesopotamia. University of Chicago Press. ISBN 978-0-226-10159-0. Charpin, Dominique (2023). "Old Babylonian Law and Justice according to Letters and Legal Documents". In Démare-Lafont, Sophie; Fleming, Daniel E. (eds.). Judicial Decisions in the Ancient Near East. SBL Press. pp. 103–222. doi:10.2307/jj.8784672. ISBN 978-1-62837-486-5. Harris, Rivkah (1969). "Notes on the Babylonian Cloister and Hearth: A Review Article". Orientalia. 38 (1): 133–145. ISSN 0030-5367. JSTOR 43079057. Harris, Rivkah (1976). "On Kinship and Inheritance in Old Babylonian Sippar". Iraq. 38 (2): 129–132. doi:10.2307/4200036. ISSN 0021-0889. Jacquet, Antoine (2013). "Family Archives in Mesopotamia during the Old Babylonian Period". In Faraguna, Michele (ed.). Archives and archival documents in ancient societies: Legal Documents in Ancient Societies IV: Trieste 30 September-1 October 2011. Edizioni Università di Trieste. pp. 63–85. ISBN 978-88-8303-460-2. De Graef, Katrien (2016). "Cherchez la femme! The Economic Role of Women in Old Babylonian Sippar". In Lion, Brigitte; Michel, Cécile (eds.). The Role of Women in Work and Society in the Ancient Near East. De Gruyter. pp. 270–295. doi:10.1515/9781614519089-016. ISBN 978-1-61451-908-9.
Sources: en.wikipedia.org
== Structure == The complete three-dimensional structure of the T. thermophilus 70S ribosome was determined using X-ray crystallography, containing mRNA and tRNAs bound to the P and E sites at 5.5 Å resolution and to the A site at 7 Å resolution. Authors found that all three tRNA binding sites (A, P, and E) of the ribosome contact all three respective tRNAs at universally conserved parts of their structures. This allows the ribosome to bind different tRNA species in precisely the same way. The translocation step of protein synthesis requires movements of 20 Å or more by the tRNAs, as they move from the A to P to E sites
In addition to his civil rights activism during the 1960s and 1970s, Sanders was active in several peace and antiwar movements while attending the University of Chicago, becoming a member of the Student Peace Union. He applied for conscientious objector status during the Vietnam War; his application was eventually turned down, by which point he was too old to be drafted. Although he opposed the war, Sanders did not criticize those who fought in it and has strongly supported veterans' benefits throughout his political career. He was briefly an organizer with the United Packinghouse Workers of America while in Chicago. He also worked on the reelection campaign of Leon Despres, a prominent Chicago alderman who opposed then mayor Richard J. Daley's Democratic Party machine. Sanders said that he spent much of his student years reading history, sociology, psychology, and the works of political authors, from Thomas Jefferson, Abraham Lincoln, John Dewey, Karl Marx, and Erich Fromm—"reading everything except what I was supposed to read for class the next day."
=== Irregular and uneven bands === It has been claimed that a variety of odd and unequal bands, including black dots, white spots or bands, and curving bands, have occurred. The block dots are removed from the blots by effective blocking. White patches develop as a result of bubbles between the membrane and gel. White bands appear in the blots when main and secondary antibodies are present in significant concentrations. Because of the high voltage used during the gel run and the rapid protein migration, smiley bands appear in the blots. The strange bands in the blot are resolved by resolving these problems.
Sources: en.wikipedia.org
=== Single-cell analysis === By decreasing the inner diameter of the primary and secondary capillaries, spatial resolution can be decreased to 20x20 μm or even smaller facilitating the analysis of individual cells. This way even various proteoforms can be measured in single cells as well as global and spatial metabolomics.
Armaan Kohli, Indian actor Bisham Kohli, Indian film personality, better known as Vishal Anand Girish Kohli (born 1983), Indian author and screenwriter Gurdeep Kohli (born 1980), Indian actor Hardeep Singh Kohli (born 1969), British presenter Himansh Kohli (born 1989), Indian actor Jas Kohli, Indian author Kuku Kohli (born 1949), Indian director, writer, editor and screenwriter Kunal Kohli (born 1969), Indian film director, producer and writer Narendra Kohli (1940–2021), Indian Hindi-language author Neelu Kohli, Indian television actress Nishi (actress) (born 1935), Indian actor Purab Kohli (born 1979), Indian actor, model and former video jockey Rahul Kohli, English actor Rajkumar Kohli (1930–2023), Indian film director Raul Kohli, English standup comedian Rochak Kohli (born 1983), Indian music director, composer, singer, instrumentalist and lyricist Sanjeev Kohli (born 1971), British Indian comedian, writer and actor Seema Kohli, Indian artist Sunita Kohli, Indian interior designer Vikas Kohli, Indian musician and music producer
=== Early life === Logan Roy's early life is elaborated in an animation made for the episode "Dundee" that was eventually cut and replaced by a scene where Kendall performs a rap song exalting his father. Roy was born on 29 October in Dundee, Scotland, United Kingdom in 1938, in a working-class family. His father died from a brain hemorrhage several years later. During World War II, he was sent with his older brother Ewan to live with his uncle Noah in Quebec, Canada. In the episode "Church and State," Ewan recalls in a eulogy that during the journey, the two brothers were stranded at sea after their ship's engines had failed. Fearing attacks by German submarines, the two did not speak or move for three days. While Logan was enrolled at a boarding school, his baby sister, Rose, arrived to Canada. After falling ill and returning home, Rose died of polio, which would cause immense guilt for the rest of Logan's life as he believed he was responsible. In the episode "Austerlitz," he claims that Noah was physically abusive towards him throughout his childhood, which is indicated by scars across Logan's back.
=== Electronic cross-matching === Electronic cross-matching is a computer-assisted analysis using data, from the donor unit (where a donor's blood is tested prior to donation) and testing done on blood samples from the intended recipient. This includes ABO/Rh typing of the unit and of the recipient, and an antibody screen of the recipient. Electronic cross-matching can only be used if a patient has a negative antibody screen, which means that they do not have any active red blood cell atypical antibodies, or they are below the detectable level of current testing methods. If all of the data entered is compatible, the computer will print a compatibility label stating that the unit is safe to transfuse.
Sources: en.wikipedia.org
It is proposed to promote lipolysis in fat tissue, the breakdown of stored fat into fatty acids and glycerol. The detailed receptor and signaling mechanisms are not fully established.
Because it is a fragment rather than full growth hormone, it is generally described as lacking growth-promoting effects. Some studies suggest it may influence fat metabolism without the same systemic growth effects, though evidence is limited.
Human trials have measured body weight, fat mass, lean mass, lipid levels, and adverse events. Most have been small or short-term, so conclusions about long-term outcomes are limited.
AOD-9604 is a synthetic peptide fragment of human growth hormone, corresponding to amino acids 176-191. It is studied for potential effects on fat metabolism, but it is not approved as a drug in most countries. Its exact mechanism remains under investigation.